Utah Medical Products (UTMD) AI Stock Analysis

• Market Cap: $213.75M
• Dividend Yield: 2.15%
• Average Volume (3M): 15.88K
• Price to Earnings (P/E): 19.2
• Beta (1Y): 0.47
• Revenue Growth: -12.35%
• EPS Growth: -17.20%
• Country: US
• Employees: 155
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.80
• Shares Outstanding: 3,203,672
• 10 Day Avg. Volume: 20,525
• 30 Day Avg. Volume: 15,884
• PEG Ratio: -1.18
• Price to Book (P/B): 1.55
• Price to Sales (P/S): 4.81
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.61
• Enterprise Value/Revenue: 3.40
• Enterprise Value/Gross Profit: 6.43
• Enterprise Value/Ebitda: 7.86
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 71 Outperform
• Price Target: $67.00 ▲(20.35% Upside)
• Action: Upgraded Date: 02/01/26
• Date: Action: Upgraded 02/01/26

The score is driven primarily by strong financial resilience (very low leverage, strong margins, and solid cash conversion), partially offset by a significant recent revenue and profit/FCF decline. Technicals are mildly supportive and valuation is reasonable with a modest dividend yield, but the operating downturn remains the key risk.

Positive Factors

Balance Sheet Health

A strong balance sheet with low leverage enhances financial stability, allowing UTMD to invest in growth opportunities without significant financial risk.

Cash Flow Generation

Strong cash flow generation supports ongoing operations and strategic investments, providing UTMD with the flexibility to fund growth initiatives and manage economic fluctuations.

Profitability

High profitability margins indicate efficient operations and cost management, which can sustain competitive advantages and shareholder returns over time.

Negative Factors

Revenue Growth Decline

Declining revenue growth could signal challenges in market expansion or product demand, potentially impacting long-term business momentum and profitability.

Earnings Growth Decline

A decline in earnings growth can affect investor confidence and limit the company's ability to reinvest in business development, potentially hindering future growth.

Market Position Challenges

Operating in a competitive market with declining revenue growth may challenge UTMD's ability to maintain its market position, affecting long-term strategic goals.

Utah Medical Products Business Overview & Revenue Model

Company Description

Utah Medical Products, Inc. (UTMD) is a leading medical device company focused on developing and manufacturing high-quality medical products primarily for the healthcare sector. Founded in 1978 and headquartered in Midvale, Utah, the company specializes in the design of innovative, proprietary products that cater to the needs of hospitals and healthcare professionals. UTMD's product lines include disposable devices used in critical areas such as neonatal care, urology, and surgical procedures, emphasizing safety and efficacy.

How the Company Makes Money

Utah Medical Products generates revenue through the sale of its medical devices to hospitals, clinics, and healthcare providers. The company's revenue model is primarily based on direct sales of its proprietary products, which are sold both domestically and internationally. Key revenue streams include sales from its neonatal product line, urology devices, and surgical instruments. Additionally, UTMD engages in partnerships with distributors and healthcare institutions to expand its market reach and increase product adoption. The company's emphasis on innovation and regulatory compliance helps maintain a competitive edge, contributing to sustained earnings through consistent demand for its medical devices.

Utah Medical Products Financial Statement Overview

Summary

Fortress balance sheet with minimal debt and strong equity base, plus high margins and solid cash conversion. However, the sharp TTM revenue contraction and step-down in earnings/FCF versus prior years materially weaken operating momentum.

Income Statement

Profitability remains a clear strength, with TTM (Trailing-Twelve-Months) gross margin ~54% and net margin ~30%—still strong for the industry. However, fundamentals have softened meaningfully: revenue is down ~50% in TTM (Trailing-Twelve-Months) versus the prior period, following declines in 2024 and 2023, and earnings have stepped down from 2021–2023 levels. Overall: high margins and solid earnings power, but a sharp recent demand/revenue contraction drives the mid-range score.

Balance Sheet

The balance sheet is exceptionally conservative. Total debt is minimal (about $0.24M in TTM (Trailing-Twelve-Months)) against ~$118M of equity, resulting in near-zero leverage and substantial financial flexibility. Returns on equity are positive (about ~10% TTM (Trailing-Twelve-Months)), though down from prior years, reflecting weaker recent profitability rather than balance-sheet stress.

Cash Flow

Cash generation is solid and high-quality: operating cash flow is strong (~$14.2M TTM (Trailing-Twelve-Months)) and free cash flow closely tracks net income (roughly 99% in TTM (Trailing-Twelve-Months)), indicating earnings are converting to cash. The key weakness is trajectory—free cash flow growth is sharply negative in TTM (Trailing-Twelve-Months) and has generally slowed since 2023, consistent with the revenue decline.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	38.52M	40.90M	50.22M	52.28M	49.05M
Gross Profit	19.88M	24.14M	30.04M	32.20M	30.92M
EBITDA	17.06M	16.44M	24.75M	26.87M	26.16M
Net Income	11.29M	13.87M	16.64M	16.47M	14.79M
Balance Sheet
Total Assets	122.54M	122.54M	135.46M	123.87M	115.64M
Cash, Cash Equivalents and Short-Term Investments	85.76M	82.98M	92.87M	75.05M	60.97M
Total Debt	0.00	338.00K	295.00K	341.00K	396.00K
Total Liabilities	3.27M	5.11M	7.14M	9.62M	8.50M
Stockholders Equity	119.27M	117.43M	128.31M	114.25M	107.14M
Cash Flow
Free Cash Flow	0.00	14.60M	21.64M	20.33M	20.65M
Operating Cash Flow	0.00	14.83M	22.28M	21.15M	21.20M
Investing Cash Flow	0.00	-208.00K	-639.00K	-818.00K	-552.00K
Financing Cash Flow	0.00	-23.84M	-4.17M	-5.48M	-10.90M

Utah Medical Products Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 55.67
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UTMD, the sentiment is Positive. The current price of 55.67 is below the 20-day moving average (MA) of 63.68, below the 50-day MA of 60.56, and below the 200-day MA of 58.15, indicating a bullish trend. The MACD of 1.80 indicates Negative momentum. The RSI at 65.42 is Neutral, neither overbought nor oversold. The STOCH value of 75.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UTMD.

Utah Medical Products Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTMD	71 Outperform	$213.75M	19.22	9.59%	2.15%	-12.35%	-17.20%
INFU	69 Neutral	$174.89M	27.28	11.54%	―	6.23%	283.88%
KRMD	59 Neutral	$220.96M	-59.11	-21.71%	―	22.12%	69.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SMTI	42 Neutral	$178.00M	-4.59	-27.19%	―	30.55%	-340.19%